Research programme: musculoskeletal therapeutics - Enobia Pharma

Drug Profile

Research programme: musculoskeletal therapeutics - Enobia Pharma

Alternative Names: MH-2-64C; Osteocrin; PHEX inhibitor 1; PHEX inhibitor 2

Latest Information Update: 22 Feb 2010

Price : $50

At a glance

  • Originator Enobia Pharma
  • Class Small molecules
  • Mechanism of Action Endopeptidase inhibitors; Metalloprotease inhibitors; Neprilysin inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bone disorders; Cartilage disorders; Fracture; Osteodystrophy; Osteoporosis; Periodontal disorders

Most Recent Events

  • 22 Feb 2010 Discontinued - Preclinical for Periodontal disorders in Canada (PO)
  • 22 Feb 2010 Discontinued - Preclinical for Osteoporosis in Canada (PO)
  • 22 Feb 2010 Discontinued - Preclinical for Osteodystrophy in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top